NRAS and melanoma: Gamitrinib, an inhibitor of heat shock protein (HSP)90, represents another possible strategy to overcome drug resistance to MAPK inhibitors [203] and has also shown activity in NRAS mutant melanoma in combination with 6-thio-2′-deoxyguanosine [207].